All Bell ceremonies

EnterNext welcomes Fermentalg on Euronext in Paris

Pierre Calleja, Chairman and CEO & Founder, rings the opening bell.

Founded in 2009 by Pierre Calleja, Fermentalg is an industrial biotechnology company that specializes in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Its patented technology allows it to target a range of fast-growing global markets, from nutrition and animal feed to cosmetics and health, green chemistry and energy. Fermentalg has already signed its 1st industrial and commercial joint-venture for the production of Omega-3 oils rich in EPA and DHA as well as several other partnerships with leading industrial groups.

EnterNext welcomes Fermentalg on Euronext in Paris

Pierre Calleja, Chairman and CEO & Founder, rings the opening bell.

Founded in 2009 by Pierre Calleja, Fermentalg is an industrial biotechnology company that specializes in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Its patented technology allows it to target a range of fast-growing global markets, from nutrition and animal feed to cosmetics and health, green chemistry and energy. Fermentalg has already signed its 1st industrial and commercial joint-venture for the production of Omega-3 oils rich in EPA and DHA as well as several other partnerships with leading industrial groups.

EnterNext welcomes TxCell on Euronext's market in Paris

Damian Marron, CEO of TxCell, opens the European trading day in Paris.

TxCell is a biotechnology group that specializes in developing customized cell immunotherapy using antigen-specific regulatory T cells (Ag-Tregs) and for the treatment of severe chronic inflammatory and autoimmune diseases.
At the end of 2013, TxCell has a portfolio of 4 products including 1 in phase II of development (Ovasave; treatment of the Crohn disease), 1 in phase I/II of development (Col-Treg; treatment of autoimmune uveitis), 1 in phase of preclinical development (Myelin-Treg; treatment of the progressive forms of multiple sclerosis) and 1 in research phase (HSP60-Treg).

EnterNext welcomes TxCell on Euronext's market in Paris

Damian Marron, CEO of TxCell, opens the European trading day in Paris.

TxCell is a biotechnology group that specializes in developing customized cell immunotherapy using antigen-specific regulatory T cells (Ag-Tregs) and for the treatment of severe chronic inflammatory and autoimmune diseases.
At the end of 2013, TxCell has a portfolio of 4 products including 1 in phase II of development (Ovasave; treatment of the Crohn disease), 1 in phase I/II of development (Col-Treg; treatment of autoimmune uveitis), 1 in phase of preclinical development (Myelin-Treg; treatment of the progressive forms of multiple sclerosis) and 1 in research phase (HSP60-Treg).

Lyxor lance le premier ETF sur PEA-PME en Bourse de Paris

Lyxor lance le premier ETF sur PEA-PME. Cet ETF s’adresse à la fois aux investisseurs souhaitant profiter de la performance des PME et du régime fiscal avantageux du PEA-PME.

Avec ce nouvel ETF, Lyxor est le premier émetteur à proposer aux investisseurs français un accès facilité à un portefeuille diversifié de PME (indice composé de 40 sociétés à avril 2014). Investir dans les PME via cet ETF permet par ailleurs de bénéficier de tous les avantages fiscaux du PEA-PME, tout en se protégeant du risque de liquidité parfois associé aux petites capitalisations. D’autres investisseurs (étrangers ou institutionnels) peuvent également être intéressés par le mode de construction fondamental de l’indice. En effet, l’univers d’investissement de cet indice Euronext PEA-PME ne fluctue pas en fonction des prix du marché, par essence volatils, mais en fonction de la situation économique réelle des entreprises. 

EnterNext welcomes Quantum Genomics on Alternext's market in Paris

Lionel Segard, CEO of Quantum Genomics, closes the European trading day in Paris.

Quantum Genomics specializes in the research and development of drugs used to treat cardiovascular, neurological, and metabolic disorders.

EnterNext welcomes Quantum Genomics on Alternext's market in Paris

Lionel Segard, CEO of Quantum Genomics, closes the European trading day in Paris.

Quantum Genomics specializes in the research and development of drugs used to treat cardiovascular, neurological, and metabolic disorders.

EnterNext welcomes Supersonic Imagine on Euronext's market in Paris

Jacques Souquet, CEO and founder of SuperSonic Imagine, opens the European trading day in Paris.

SuperSonic Imagine develops echographic systems based on a quantitative real-time tissue elasticity imaging concept. Products are intended for diagnosing cancers (breast, abdomen, liver, thyroid, prostate, etc.), vascular pathologies, muscle problems, and gynecological diseases. The group also offers maintenance and technical support services.

EnterNext welcomes Supersonic Imagine on Euronext's market in Paris

Jacques Souquet, CEO and founder of SuperSonic Imagine, opens the European trading day in Paris.

SuperSonic Imagine develops echographic systems based on a quantitative real-time tissue elasticity imaging concept. Products are intended for diagnosing cancers (breast, abdomen, liver, thyroid, prostate, etc.), vascular pathologies, muscle problems, and gynecological diseases. The group also offers maintenance and technical support services.

Euronext welcomes Genomic Vision on Euronext in Paris

Genomic Vision specializes in developing genetic diseases diagnosis tests and cancer genomic analysis. The group uses molecular combing technology which allows direct visualization of DNA individual molecules in order to detect the quantitative and qualitative changes of the genome and determine their role in targeted pathology.

Euronext welcomes Genomic Vision on Euronext in Paris

Genomic Vision specializes in developing genetic diseases diagnosis tests and cancer genomic analysis. The group uses molecular combing technology which allows direct visualization of DNA individual molecules in order to detect the quantitative and qualitative changes of the genome and determine their role in targeted pathology.

The listing of the bonds (Medium Term Notes) issued by Brussels-Captital Region

On 7 April 2014, Guy Vanhengel, Minister of Finance and Budget of the Brussels-Capital Region opened the European stock markets with a Bell Ceremony at Euronext Brussels to celebrate the first listing of the Medium Term Notes issued by Brussels-Capital Region. The bonds are listed with a total amount of 35.000.000 euro. The redemption dates are 2029 and 2044. The interest rates are respectively 2.864% and 3.375%.  ING and Belfius were the coordinators.

_{Guy Vanhengel, Minister of Finance and Budget of the Brussels-Capital Region at listing ceremony Medium Term Notes}

The listing of the bonds (Medium Term Notes) issued by Brussels-Captital Region

On 7 April 2014, Guy Vanhengel, Minister of Finance and Budget of the Brussels-Capital Region opened the European stock markets with a Bell Ceremony at Euronext Brussels to celebrate the first listing of the Medium Term Notes issued by Brussels-Capital Region. The bonds are listed with a total amount of 35.000.000 euro. The redemption dates are 2029 and 2044. The interest rates are respectively 2.864% and 3.375%.  ING and Belfius were the coordinators.

_{Guy Vanhengel, Minister of Finance and Budget of the Brussels-Capital Region at listing ceremony Medium Term Notes}

The listing of the bonds (Medium Term Notes) issued by Brussels-Captital Region

On 7 April 2014, Guy Vanhengel, Minister of Finance and Budget of the Brussels-Capital Region opened the European stock markets with a Bell Ceremony at Euronext Brussels to celebrate the first listing of the Medium Term Notes issued by Brussels-Capital Region. The bonds are listed with a total amount of 35.000.000 euro. The redemption dates are 2029 and 2044. The interest rates are respectively 2.864% and 3.375%.  ING and Belfius were the coordinators.

_{Guy Vanhengel, Minister of Finance and Budget of the Brussels-Capital Region at listing ceremony Medium Term Notes}

Initial public offering of Genticel on Euronext Paris

Benedikt Timmerman, CEO & Founder of Genticel, opens the trading day in Paris.

Genticel is a French pharmaceutical company, specialising in the development of therapeutic vaccines aimed at eliminating, at an early stage, the Human Papilloma Virus (HPV) responsible for cervical cancer.

Initial public offering of Genticel on Euronext Paris

Benedikt Timmerman, CEO & Founder of Genticel, opens the trading day in Paris.

Genticel is a French pharmaceutical company, specialising in the development of therapeutic vaccines aimed at eliminating, at an early stage, the Human Papilloma Virus (HPV) responsible for cervical cancer.

EnterNext welcomes Oncodesign on Alternext in Paris

Philippe Genne, CEO of Oncodesign, opens the European trading day in Paris.

Oncodesign specializes in the research and development of drugs for the treatment of cancer. The group provides preclinical pharmacological evaluation services in the oncology field.

EnterNext welcomes Oncodesign on Alternext in Paris

Philippe Genne, CEO of Oncodesign, opens the European trading day in Paris.

Oncodesign specializes in the research and development of drugs for the treatment of cancer. The group provides preclinical pharmacological evaluation services in the oncology field.